electroCore (ECOR) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
electroCore (ECOR) has outperformed MaxCyte (MXCT) over the past year, gaining 84.7% versus a loss of 40.0%. Over five years, ECOR leads with a -36.4% price change compared with -90.8% for MXCT. MaxCyte is the larger company by market cap ($105.3 million vs $85.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | MXCT |
|---|---|---|
| Share price | $9.51 | $1.02 |
| Market cap | $85.74M | $105.27M |
| 1-day change | -2.16% | -1.92% |
| YTD return | +112.04% | -34.19% |
| 1-year return | +84.66% | -40.00% |
| 5-year return | -36.41% | -90.75% |
| EPS (TTM) | $-1.65 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $1.87 |
| 52-week low | $4.41 | $0.643 |
| Distance from 52-week high | -25.12% | -45.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +101.58% | +302.94% |
| Average volume | 80.51K | 668.82K |
| Shares outstanding | 9.02M | 103.21M |
| Employees | 83 | 91 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ECOR has outperformed MXCT by 124.7 percentage points over the past year.
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Healthcare · Medical Devices · 83 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
ECOR vs MXCT FAQ
Which is bigger, electroCore or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $105.27M compared with $85.74M for electroCore (ECOR).
Which stock has performed better over the past year, ECOR or MXCT?
ECOR returned +84.66% over the past 12 months, compared with -40.00% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and MaxCyte in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.